Researchers have elucidated the disease risk underlying a biomarker predictive of shorter lifespan. Researchers have been able to unravel the disease burden that unde...

Excellent safety profile reported so far, results expected summer 2019 Liège, Belgium, November 5, 2018 – Imcyse, who develop active specific immunotherapies for the ...

Candidate molecules have the potential to treat multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and systemic inflammatory disea...

First dose has been administered in the multiple-center study  BN-Brachyury for the treatment of chordoma received FDA Orphan Drug Designation in May 2018 COPEN...

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation...